Selvita S.A. (WSE:SLV)

Market Cap	576.36M +12.9%
Revenue (ttm)	359.93M +0.0%
Net Income	-3.65M
EPS	-0.21
Shares Out	18.36M
PE Ratio	n/a
Forward PE	35.63
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,261
Open	31.95
Previous Close	31.40
Day's Range	30.60 - 31.95
52-Week Range	28.10 - 49.40
Beta	0.04
Analysts	Buy
Price Target	47.32 (+54.64%)
Earnings Date	Sep 17, 2026

About Selvita

Selvita S.A. provides drug discovery, drug development, and contract testing services in Poland. The company offers computer-aided drug design and artificial intelligence solutions, including structure-based drug design, virtual screening, and bioinformatics; medicinal and synthetic, analytical, and solid state chemistry, as well as process chemistry and scale up, and compound management and libraries; structural biology, fragment-based drug discovery, protein production, modification, and characterization; vitro assays and model, mechanistic a...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2007
• Employees: 691
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: SLV

Analyst Summary

According to 6 analysts, the average rating for SLV stock is "Buy." The 12-month stock price target is zł 47.32, which is an increase of 54.64% from the latest price.

Price Target

zł 47.32

(54.64% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 6, 2026

Data Sources Report a data error